Comparison of contemporaneous therapeutic drug monitoring in CSF and blood-plasma

Comparison of contemporaneous therapeutic drug monitoring in CSF and blood-plasma - LeMeC (Levels of Medication in Cerebrospinal fluid)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00031392

Enrollment

Registered

2023-03-01

Start date

2023-04-21

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z98.2

Interventions

Group 1: Population: - all critically ill patients with a temporary CSF-drainage and - antiinfective therapy Method of diagnostics: - Measuring levels of antiinfective medication in CSF and in bloo

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Existence of a continuous temporary CSF-drainage

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
We aim to calculate CSF-Serum-ratios of several antiinfectives (e.g. Cefotaxime, Ceftazidime, Linezolide) by chromatographic or immunologic daily or bidiurnal measurements of their respective levels in contemporaneously taken CSF- and blood-probes	—

Secondary

Measure	Time frame
Influence of type of drainage and type of disease on the CSF-Serum-ratio of an antiinfective	—

Countries

Germany

Contacts

Public ContactCaspar Stephani

Universitätsmedizin Göttingen

cstephani@med.uni-goettingen.de01753431572

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026